Loading…
← CockpitCompetitor Analysis › SUVEN.NS Suven Life Sciences LimitedOpen in the cockpit ↗

Suven Life Sciences LimitedSUVEN.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major
Momentum weak 21
Mkt cap
$803M
US dollars, full cap
Free float
34%
of shares outstanding
$/day
$1.17M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 18.0%
Hurdle
n/a
no reverse DCF
Close · INR₹265.65
1D-1.1%
1W-4.4%
1M-8.4%
3M-21.8%
6M-1.4%
YTD+59.8%
1Y+41.3%
ATR %5.0%
Beta1.18
52w lowhigh34.1% off high

What Suven Life Sciences does

Employees: 181

Suven Life Sciences at a glance

Size Suven Life Sciences (SUVEN.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $803M, the 671st largest of 1,066 India companies the cockpit tracks. Shares closed at ₹265.65 on 18 Nov 2026.

Performance Over six months the shares fell 1.4%, against -8.3% for the median peer and +3.8% for the India market (cap-weighted) — 7th highest of 19 in its peer set.

Growth Revenue grew 55.1% over the last twelve months (peer median +2.1%); the operating margin is -4,451.6% (peer median 6.9%).

Valuation It trades at 789.4× enterprise value to sales against a peer median of 3.1× (most expensive of 18).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026SUVEN.NS 99Peer median 92
Six months, rebased to 100: Suven Life Sciences against the median of its 20 peers (local-currency closes).

Suven Life Sciences financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹90.9M₹71.1M₹66.6M₹117M₹135M
Revenue growth—+7%-43%-14%—
Gross profit-₹443M-₹242M-₹213M-₹148M-₹120M
EBITDA-₹3.97B-₹2.84B-₹1.65B-₹1.28B-₹1.25B
Net income-₹3.82B-₹2.76B-₹1.61B-₹1.05B-₹1.18B
Free cash flown/a-₹3.02B-₹1.86Bn/a-₹1.06B
Capital expendituren/a₹50.8M₹373M₹0₹28.9M
Total debt₹160M₹167M₹0₹7.10M₹16.1M

Quarterly statements and history in the cockpit →

Suven Life Sciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-50%-25%0%+25%COLL688073RIGLSANOFI6078ORICGUDIRWD002349ARDX002082603229000411300267BLISSGVSSUVEN.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Suven Life Sciences is the large dot.

Fundamentals: revenue growth against valuation

-50%-25%0%+25%+50%0×250×500×750×COLL688073SANOFIGUDIRWD002082000813BLISSGVSLXRXSUVEN.NSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Suven Life Sciences is the large dot.

Suven Life Sciences competitors and peer comparison

How Suven Life Sciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Suven Life Sciences against its 20 peers (data as of 18 Nov 2026)
MeasureSUVEN.NSPeer medianRank in peer set
1-month return-8.4%-2.9%8th lowest of 19
6-month return-1.4%-8.3%7th highest of 19
Distance from 52-week high-34.1%-33.5%10th highest of 19
Revenue growth (TTM)+55.1%+2.1%highest of 19
Operating margin-4,451.6%6.9%lowest of 19
EV / Sales789.4×3.1×most expensive of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Suven Life Sciences SUVEN.NSIndia$803M-1%+55%-4,452%789.4×n/an/a
Collegium Pharmaceutical COLLUnited States$806M-24%+8%15%2.3×-2.6%+20.3%
Bide Pharmatech 688073.SSChina$801M+10%+10%19%3.1×13.9%+27.7%
Rigel Pharmaceuticals RIGLUnited States$801M+48%+2%26%2.5×1.5%+22.1%
Sanofi India SANOFI.NSIndia$797M0%-6%26%4.1×16.3%-8.7%
Hygeia Healthcare 6078.HKHong Kong$811M-3%+2%14%1.8×4.6%+22.5%
Oric Pharmaceuticals ORICUnited States$795M-9%n/an/an/an/an/a
Knight Therapeutics GUD.TOCanada$792M+41%+36%6%1.8×6.6%+17.7%
Ironwood Pharmaceuticals IRWDUnited States$791M+22%+18%63%2.6×n/an/a
Bambusa Therapeutics BBTXUnited States$791Mn/an/an/an/an/an/a
Jinghua Pharmaceutical 002349.SZChina$785M-8%+2%20%3.1×-2.5%+2.6%
Ardelyx ARDXUnited States$784M-50%+18%-8%1.6×n/an/a
Wanbangde Pharmaceutical 002082.SZChina$823M-52%-38%-10%7.0×27.7%-39.5%
Zhejiang Ausun Pharmaceutical 603229.SSChina$824M-34%+1%0%6.5×n/an/a
Zhejiang Int'l 000411.SZChina$783M-21%+3%3%0.3×n/an/a
Dezhan Healthcare 000813.SZChina$825M-33%-10%-121%13.8×n/an/a
Sichuan Neautus Traditional Chinese 2206.HKHong Kong$779Mn/a+7%8%n/an/an/a
Hunan Er-Kang Pharmaceutical 300267.SZChina$829M-40%-14%-29%4.7×n/an/a
Bliss GVS Pharma BLISSGVS.NSIndia$777M+141%+25%18%6.7×33.9%+10.1%
Guizhou Xinbang Pharmaceutical 002390.SZChina$771M-7%-13%4%0.9×-3.8%-0.8%
Lexicon Pharmaceuticals LXRXUnited States$766M-22%-46%-147%16.7×n/an/a

Questions

Which companies are Suven Life Sciences's closest peers?
The cockpit's peer set: Collegium Pharmaceutical (COLL), Bide Pharmatech (688073.SS), Rigel Pharmaceuticals (RIGL), Sanofi India (SANOFI.NS), Hygeia Healthcare (6078.HK), Oric Pharmaceuticals (ORIC), Knight Therapeutics (GUD.TO), Ironwood Pharmaceuticals (IRWD).
Is Suven Life Sciences expensive compared with its peers?
On ev / sales it trades at 789.4× against a peer median of 3.1×, most expensive of 18 in its peer set.
How has Suven Life Sciences stock performed?
Over six months to 18 Nov 2026 the shares returned -1.4% against -8.3% for the median peer; over one year +41.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.